0.26
+0.0019(+0.75%)
Currency In USD
| Previous Close | 0.26 |
| Open | 0.25 |
| Day High | 0.27 |
| Day Low | 0.25 |
| 52-Week High | 2.63 |
| 52-Week Low | 0.22 |
| Volume | 176,503 |
| Average Volume | 10.78M |
| Market Cap | 13.2M |
| PE | -0.03 |
| EPS | -8.31 |
| Moving Average 50 Days | 0.35 |
| Moving Average 200 Days | 1.08 |
| Change | 0 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.26 as of March 15, 2025 at a share price of $0.257. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $3.71 as of March 15, 2025 at a share price of $0.257.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
GlobeNewswire Inc.
Feb 26, 2025 1:30 PM GMT
Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programsCAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for t
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
GlobeNewswire Inc.
Jan 28, 2025 1:30 PM GMT
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced s
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
GlobeNewswire Inc.
Jan 14, 2025 1:30 PM GMT
New data from proof-of-concept study provides roadmap for treatment of ovarian cancerCAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, toda